New York City-based startup Trovo Health, which offers an AI-powered platform backed by a multidisciplinary clinical team that assists providers with complex tasks, announced its launch with $15 million in seed funding.
Oak HC/FT led the round. Cofounder and managing partner at Oak HC/FT, Andrew Adams, will join Trovo’s board of directors.
The company will use the funds to build its technology platform, clinical operations and leadership team.
“Adding new practice capabilities, both internal and patient facing, has always been a challenge for practices,” Niren Gandra, CEO and cofounder of Trovo Health, said in a statement. “By combining specialty-specific AI with expert clinical team members, we can help providers tackle historically difficult problems with a click of a button.”
Alaffia Health, which produces genAI solutions for health insurance claims, announced it secured $10 million in a Series A funding round led by FirstMark Capital, bringing its total raise to $17.6 million.
Aperture Venture Capital also participated in the round alongside other investors.
Alaffia has earmarked the funds to further invest in AI research, develop its product and expand its commercial footprint.
“We appreciate the strong support the Aperture VC team has shown over the last three years. Their guidance has been invaluable in giving us the room as founders to pioneer the use of new AI tools across the healthcare claims ecosystem,” TJ Ademuliyi, Alaffia’s CEO, said in a statement.
Paris-based digital health startup Klineo announced it raised €2 million ($2.14 million) for its oncology-focused AI-powered clinical-trial platform.
BPI and business angels participated in the round.
The startup offers two interfaces, one for doctors and another for patients. The AI-enabled platform allows users to directly connect to centers offering clinical trials.
Klineo plans to use the funds to expand its offerings to address clinical trials for all types of cancer.
“Today, too few patients benefit from a clinical trial because the search for one is a very tedious process. At Klineo, we offer a reliable, intuitive and fast solution that finally gives doctors and patients, wherever they are treated, the possibility of easily finding new therapeutic options adapted to each situation, and which ultimately enables medical research to progress,” Dr. Arnaud Bayle, oncologist and cofounder of Klineo, said in a statement.
